Vitale G C, Reed D N, Nguyen C T, Lawhon J C, Larson G M
Department of Surgery, University of Louisville School of Medicine, KY 40292, USA.
Surg Endosc. 2000 Mar;14(3):227-31.
Endoscopic placement of biliary stents is an effective initial treatment for jaundice and cholangitis caused by common bile duct (CBD) strictures secondary to chronic pancreatitis; however, the role of endoscopic treatment for long-term management of these strictures is less clear. In 1992, we designed a protocol of balloon dilatation and stenting for > or =12 months. This study evaluates endoscopic therapy as a definitive long-term treatment for these strictures. We have treated 25 patients with this protocol.
All patients had an endoscopic sphincterotomy, balloon dilatation of the stricture, and then placement of a polyethylene stent (7-11.5 F). Stents were exchanged at 3-4-month intervals to avoid the complications of clogging and cholangitis. We were particularly interested in how many patients would achieve resolution of the stricture and tolerate removal of the stent.
The length of the CBD strictures ranged from 8 to 40 mm. Within days of stenting, all patients achieved relief of jaundice and cholestasis. Complications consisted of six episodes of cholangitis and nine episodes of pancreatitis. There were no deaths. Twenty of the 25 patients are now stent-free after an average stenting period of 13 months (range, 3-28). To date, there has been no recurrence of stricture, for a mean of 32 months. Three patients still have stents in place, and two patients required operation--one for persistent stricture and recurrent cholangitis after 8 months of stenting, and one for a mass in the head of the pancreas that was thought to be cancer.
Our results indicate that these strictures will respond and dilate after a course of stenting in 80% of patients, with an acceptable morbidity. Although these are medium-term results at 32 months, we would expect most recurrences within the 1st year following stent removal. In some cases, stenting is necessary for >12 months. Thus, the data suggest that endoscopic stenting provides definitive treatment in most patients with CBD stricture due to chronic pancreatitis and may be considered a viable alternative to standard surgical bypass.
内镜下放置胆管支架是治疗慢性胰腺炎继发胆总管(CBD)狭窄所致黄疸和胆管炎的一种有效的初始治疗方法;然而,内镜治疗对这些狭窄的长期管理作用尚不清楚。1992年,我们设计了一项持续≥12个月的球囊扩张和支架置入方案。本研究评估内镜治疗作为这些狭窄的确定性长期治疗方法的效果。我们已用该方案治疗了25例患者。
所有患者均接受内镜括约肌切开术、狭窄部位的球囊扩张,然后置入聚乙烯支架(7 - 11.5F)。每隔3 - 4个月更换支架以避免堵塞和胆管炎并发症。我们特别关注有多少患者狭窄能够缓解并耐受支架取出。
CBD狭窄长度为8至40毫米。支架置入数天内,所有患者黄疸和胆汁淤积均得到缓解。并发症包括6次胆管炎发作和9次胰腺炎发作。无死亡病例。25例患者中有20例在平均置入支架13个月(范围3 - 28个月)后不再需要支架。迄今为止,狭窄无复发,平均随访32个月。3例患者仍留置支架,2例患者需要手术——1例在支架置入8个月后因持续性狭窄和复发性胆管炎手术,另1例因胰头肿物考虑为癌而手术。
我们的结果表明,80%的患者在经过一个疗程的支架置入后狭窄会有反应并扩张,且发病率可接受。尽管这是32个月的中期结果,但我们预计大多数复发会在支架取出后的第1年内出现。在某些情况下,支架置入需要超过12个月。因此,数据表明内镜下支架置入为大多数慢性胰腺炎所致CBD狭窄患者提供了确定性治疗,可被视为标准手术旁路的可行替代方法。